Mikael Lindström

PhD degree in Experimental Oncology 2004 and Docent in Experimental Pathology obtained 2012 at Karolinska Institutet i Stockholm, Sweden.

We are specifically interested in molecular mechanisms underlying the regulation of ribosome biogenesis, how the cell senses errors in the complex process of ribosome biogenesis and how these processes in turn can be used in the development of novel anti-cancer therapies. To investigate ribosome biogenesis and nucleolar structure, the team uses various microscopy technologies, ribosome profiling, rDNA assays, transcriptomics, translatomics, and proteomics. We also work a lot with small molecules and functional screens. Main lines and interests of research: 1. Characterization of ribosome biogenesis regulatory proteins and potential role in cancer development, biomarker discovery for personalized cancer medicine. 2. Regulation of ribosome biogenesis and protein synthesis in normal CNS cells and in glioma, including heterogeneity of ribosome in relation to glioma cellular diversity. 3. Targeting of ribosome biogenesis or mature ribosome function in cancer. 4. Functional studies of ribosomal proteins. 5. Together with Prof Sinisa Volarevic, Univ of Rijeka, Croatia, we investigate the role of RPL24 and p53 in disease. 

I have evaluated manuscripts for the following journals among others

Oncogene, Nature, EMBO Rep, EMBO J, Nature Cell Biology, J Biol Chem, Mol Cell Biol, Proteins, J. of Clinical Investigation, Mol Cell, Intl. J of Cancer, Int J Mol Sciences, Cancer, Cancers, J Cytology and Histology, J Mol Biol, PLoS One, FEBS Letters, FEBS J, Future Oncology, Cell Proliferation, Biochem J, Scientific Reports, Tumor Biology, Current Drug Targets, Cytotherapy, Nature Communications, J Cell Science, Cell Reports, Cell Cycle, Chemistry Biology, Blood, Pharmaceuticals, Biochem Soc Trans, Cells, Oncotarget, Int J of Dev Neuroscience, Cellular Physiology and Biochemistry, BMC Biotechnology, BMC Molecular Biology, Bioscience Reports, Cancer Res, Elife, J Cellular Physiology, J Oncology, BBA Mol Cell, Comm Biol, Metabolites, Ebiomedicine, ACS Chemical Biology, BBA Molecular Res, Biomarkers, JCI Insight, BioEssays, Cell Death and Disease, Cell Death and Differentiation, Biomedicines, Breast Cancer Research, Pathogens, Signal Transduction and Targeted Therapies, Biomolecules and Biomedicine, Histology and Histopathology, Epigenetics and Chromatin, Mol Oncol, Nucleic Acids Res Cancer, iScience, Int J Cancer, Discover Oncology, Trends Cell Biology, Cell Proliferation and many others.

Grant evaluator 2010-2024

NWO Vidi Scheme for Innovational Research Incentives Scheme Netherlands, AICR Assoc International Cancer Research UK, YRC Yorkshire Cancer Res UK, Semaphore FRS FNRS BE, Romanian national development and innovation council uefiscdi, German-Israeli Foundation for Scientific Research and Development,  Czech Science Foundation GACR, National Science Centre NCN Poland, INCa the French National Cancer Institute France, Fondation contre le Cancer Grant Belgian Foundation against Cancer, Croatian Science Foundation Croatia, Agence Nationale de la Recherche France, Evaluator of Baillet Latour Grant for Medical Research and Baillet Latour Prize GMR NL, European Science Foundation ESF including FWO grants and many others Worldwide Cancer Res, SNSF Innosuisse BRIDGE, UK research and innovation UKRI, INSERM Cancer PCSI France and others. 

Supervision

Co-supervisor: Dr Tamador Elsir, PhD 2010-06-04, KI 
Co-supervisor: Dr Inga Nazarenko, PhD 2011-09-30, KI
Co-supervisor: Dr Karl Holmberg-Olausson, PhD 2015-06-01, KI

Main supervisor: Dr Kaveh Moazemi Goudarzi, PhD 2018-04-27, KI
Main supervisor: Dr Asimina Zisi, PhD 2022-10-28, KI

Service to the universities

Pre-examiner of doctoral dissertation: 16 (2009-2024)
Half time review for PhD: 20 (2012-2024)
Chairman of PhD defense: 8 (2015-2024)
Examiner of MSc or BSc thesis 16 (2012-2018)
Opponent: 1

Following courses I have taken

Basic pedagogics for university lecturers GHPH09

Postgraduate supervisor training course KI

Leadership education UGL, KI

Web courses for supervisors

I have over 600 teaching hours in cell biology, oncology, and biochemistry for students at the medical and biomedical programs, including molecular oncology and biostatistics (BioMed), and Molecular Medicine course, cell biology. At the medical program biochemistry in the DFM1 and BV2 courses. I have been teaching also at the postgraduate course level, at the Cancer Cell cycles and Cancer Cell metabolism courses. I have co-organized a course on Brain Tumors. I currently also teach biochemistry at the KI prep course for foreign (non EU) medical doctors that will take knowledge test for licence to practice medicine in Sweden. 

Supervision to doctoral degree

• Asimina Zisi, RNA Polymerase I inhibition: mechanism and exploitation in cancer treatment, 2022
• Kaveh Goudarzi, Functional investigation of prognostic biomarkers and therapeutic targets in glioma brain tumors, 2018
• Karl Holmberg Olausson, Molecular subclassification, stem cell markers and growth regulatory pathways in gliomas, 2015
• Inga Nazarenko, Modeling PDGF-driven gliomagenesis in the mouse
• Tamador Elsir, Transcription factors PROX1 and p53 in cancer development, 2010